GlassScriptPhysician profile
Meera Patel
NPI 1891180501
$2,272.65
in general payments reported to CMS, 2019-2025
20 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2021: $124 · 2022: $864 · 2023: $26.06 · 2024: $315 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $494.69 | 2019-2025 | Alecensa, Tecentriq |
| Astellas Pharma US INC | $289.95 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $285.60 | 2022-2025 | Libtayo |
| Aveo Pharmaceuticals, INC. | $167.70 | 2021-2022 | |
| Janssen Biotech, INC. | $159.03 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $133.85 | 2019-2025 | Opdualag |
| Alexion Pharmaceuticals, INC. | $99.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $91.37 | 2022 | |
| Vertical Pharmaceuticals, LLC | $81.19 | 2019 | |
| Sanofi-Aventis U.S. LLC | $74.99 | 2019 | |
| Amgen INC. | $66.88 | 2022 | |
| Merck Sharp & Dohme LLC | $37.07 | 2022 | |
| Abbvie INC. | $33.07 | 2022 | |
| Medline Industries LP | $26.77 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $24.04 | 2022 | |
| Lilly USA, LLC | $21.16 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.23 | 2022 | |
| Kerr Corporation | $13.03 | 2023 | Harmonize |
| Nobel Biocare USA | $13.03 | 2023 | Nobelactive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meera Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.